Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.10 USD
Change Today -0.02 / -0.28%
Volume 110.4K
As of 8:04 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc (MDGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - $9.63
52 Week Low
12/4/14 - $3.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDGENICS INC (MDGN)

Related News

No related news articles were found.

medgenics inc (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc (MDGN) Details

Medgenics, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. It develops transduced autologous restorative gene therapy, TARGT platform to provide protein and peptide therapies to treat a range of chronic diseases and conditions. The company’s lead product candidate is MDGN-201, which is in the Phase I/II clinical trials for the treatment of end stage renal disease. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

40 Employees
Last Reported Date: 02/13/15
Founded in 2000

medgenics inc (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $765.0K
Chief Financial Officer
Total Annual Compensation: $565.0K
Chief Legal Officer
Total Annual Compensation: $154.0K
Chief Scientific Officer
Total Annual Compensation: $660.0K
Compensation as of Fiscal Year 2014.

medgenics inc (MDGN) Key Developments

Medgenics, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Medgenics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, operating loss was USD 7,888,000 against USD 5,235,000 a year ago. Loss before taxes on income was USD 8,921,000 against USD 5,352,000 a year ago. Loss was USD 8,922,000 against USD 5,357,000 a year ago. Basic and diluted loss per share was USD 0.36 against USD 0.28 a year ago.

Medgenics, Inc., Q1 2015 Earnings Call, Apr 17, 2015

Medgenics, Inc., Q1 2015 Earnings Call, Apr 17, 2015

Medgenics, Inc., Annual General Meeting, Apr 16, 2015

Medgenics, Inc., Annual General Meeting, Apr 16, 2015., at 10:00 US Eastern Standard Time. Location: The Westin New York at Times Square, 270 West 43rd Street. Agenda: To consider and elect seven persons to serve on Board of Directors until the next annual meeting of stockholders and until their respective successors are duly elected and qualified; to consider and ratify the appointment of Kost Forer Gabbay & Kasierer a member of Ernst & Young Global, as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to consider and transact such other proper business as may come before the meeting and any adjournment or postponement at the meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $7.10 USD -0.02

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at